Orbion announces application for ESA BSGN/MEDES accelerator

Did you know how Orbion and its Astra AI models got their names?

When Orbion’s founders Aniruddh Goteti and Çağlar Bozkurt were looking into groundbreaking science applications, they came across reports of life science experiments being sent into space. Unexpectedly, this was not just to study the effects of space on astronauts’ bodies: low gravity could also solve terrestrial problems, such as obtaining good quality protein crystals for medical research. This was the inspiration behind Orbion’s core idea: helping researchers solve problems that are so difficult that sometimes you have to put your research in a rocket and hope for the best.

Now, Orbion is fulfilling the promise behind its name. In collaboration with SpacePharma and Mimotype, we have applied to the European Space Agency BSGN/MEDES accelerator program, which aims to foster promising biomedical research in orbit. Our goal is to leverage unique protein crystallisation data from low-gravity experiments to strengthen research and data predictions back on Earth, ultimately helping scientists to get insights into their proteins – with no rockets needed.